Holen Sie sich die Stockscreener-App
4.42
9.14%
-0.45
Schlusskurs vom Vortag:
$4.87
Offen:
$4.85
24-Stunden-Volumen:
646.46K
Relative Volume:
1.01
Marktkapitalisierung:
$246.70M
Einnahmen:
$40.37M
Nettoeinkommen (Verlust:
$-119.72M
KGV:
-2.1665
EPS:
-2.0402
Netto-Cashflow:
$-135.06M
1W Leistung:
+13.46%
1M Leistung:
+30.53%
6M Leistung:
+5.86%
1J Leistung:
+8.86%
1-Tages-Spanne:
$4.3501
$4.91
1-Wochen-Bereich:
$3.87
$5.478
52-Wochen-Spanne:
$2.645
$5.55
Voyager Therapeutics Inc Stock (VYGR) Company Profile
Firmenname
Voyager Therapeutics Inc
Sektor
Branche
Telefon
857-259-5340
Adresse
75 HAYDEN AVENUE, LEXINGTON, MA
Compare VYGR vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VYGR
Voyager Therapeutics Inc
|
4.437 | 270.77M | 40.37M | -119.72M | -135.06M | -2.0402 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.68 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
747.28 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
704.66 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.76 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.67 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Voyager Therapeutics Inc Stock (VYGR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-02 | Eingeleitet | Citigroup | Buy |
| 2024-11-29 | Fortgesetzt | Wedbush | Outperform |
| 2024-10-16 | Eingeleitet | Leerink Partners | Outperform |
| 2024-03-26 | Eingeleitet | Guggenheim | Buy |
| 2024-03-19 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-03-07 | Eingeleitet | Citigroup | Buy |
| 2024-01-02 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-05-10 | Eingeleitet | Truist | Buy |
| 2023-03-10 | Eingeleitet | Oppenheimer | Outperform |
| 2021-10-07 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-02-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2021-02-03 | Herabstufung | BTIG Research | Buy → Neutral |
| 2021-02-03 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-12-24 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2020-12-23 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-11-10 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2020-11-10 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-03-19 | Eingeleitet | The Benchmark Company | Buy |
| 2020-02-06 | Eingeleitet | Oppenheimer | Outperform |
| 2018-11-15 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2018-09-10 | Fortgesetzt | BTIG Research | Buy |
| 2018-09-10 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2018-06-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-03-12 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2018-03-12 | Herabstufung | Wedbush | Outperform → Neutral |
| 2018-02-02 | Eingeleitet | Morgan Stanley | Overweight |
| 2017-11-28 | Fortgesetzt | Piper Jaffray | Overweight |
| 2017-10-31 | Eingeleitet | Robert W. Baird | Outperform |
| 2017-10-27 | Eingeleitet | Canaccord Genuity | Buy |
| 2017-10-23 | Bestätigt | Stifel | Buy |
| 2017-10-12 | Eingeleitet | Raymond James | Outperform |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-07-28 | Fortgesetzt | Stifel | Buy |
Alle ansehen
Voyager Therapeutics Inc Aktie (VYGR) Neueste Nachrichten
Is Voyager Therapeutics (VYGR) Balancing Pipeline Ambition With Sustainable Losses After Its 2025 Results? - simplywall.st
Does Voyager Therapeutics’ (VYGR) Widening Annual Loss Redefine the Risk-Reward in Its Neurology Pipeline? - Yahoo Finance
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Voyager Therapeutics (VYGR) Gets a Buy from H.C. Wainwright - The Globe and Mail
Voyager Therapeutics Faces Rising Tariff and U.S.–China Geopolitical Risks as BIOSECURE Act Threatens Key Chinese CDMO Partnerships - TipRanks
Voyager Therapeutics (VYGR) Q4 Loss Of US$27 Million Reinforces Bearish Profitability Concerns - simplywall.st
Voyager Therapeutics, Inc. 2025 Annual Report: Key Risks, Forward-Looking Statements, and Business Overview - Minichart
Voyager Therapeutics Inc earnings beat by $0.05, revenue topped estimates - Investing.com UK
Voyager Therapeutics (VYGR) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Voyager Therapeutics Q4 2025 Financial Report: Revenue Surpasses EstimatesNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Voyager (VYGR) Surpasses Q4 Revenue Expectations, Sets Strategic Vision for 2026 - GuruFocus
Voyager Therapeutics: Fourth Quarter Earnings Overview - Bitget
Gene therapy pioneer Voyager Therapeutics Inc (stock code: VYGR) announced that by the end of fiscal year 2025, the company held strong cash and cash equivalents totaling $202 million. - Bitget
Voyager Therapeutics (NASDAQ:VYGR) Announces Earnings Results, Beats Expectations By $0.08 EPS - MarketBeat
Voyager Therapeutics: Q4 Earnings Snapshot - 10TV
Voyager Therapeutics reports Q4 2025: $15.3M Q4 collaboration revenue, $119.7M full-year net loss - TradingView
Voyager Therapeutics 2025 10-K: Collaboration revenue $40.4M, Net loss $(119.7)M - TradingView
Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results - GlobeNewswire
Is Voyager Therapeutics Inc. stock trading at a premium valuation2026 Summary & Expert-Curated Trade Recommendations - Naître et grandir
Will Voyager Therapeutics Inc. stock gain from lower inflationEarnings Growth Report & Fast Entry Momentum Alerts - mfd.ru
Voyager Therapeutics Inc expected to post a loss of 51 cents a shareEarnings Preview - TradingView
Voyager Therapeutics (VYGR) to Release Quarterly Earnings on Tuesday - MarketBeat
Voyager Therapeutics Touts Tau, Gene Therapy and NeuroShuttle Roadmap, Sees Cash Runway Into 2028 - Defense World
Voyager Therapeutics at Oppenheimer Conference: Strategic Insights on Alzheimer’s By Investing.com - Investing.com Canada
Todd Alfred Carter Sells 4,174 Shares of Voyager Therapeutics (NASDAQ:VYGR) Stock - MarketBeat
Voyager Therapeutics (NASDAQ:VYGR) CFO Sells $17,598.36 in Stock - MarketBeat
Voyager Therapeutics (NASDAQ:VYGR) CEO Alfred Sandrock Sells 14,197 Shares - MarketBeat
Robin Swartz, Voyager Therapeutics COO, sells $24k in VYGR stock - Investing.com Canada
Alfred Sandrock, Voyager Therapeutics CEO, sells $53806 in stock By Investing.com - Investing.com Canada
Voyager Therapeutics CFO sells $17,598 in stock By Investing.com - Investing.com Canada
VYGR | Voyager Therapeutics, Inc. Common FinancialsIncome Statement - Quiver Quantitative
Voyager Therapeutics (VYGR) CFO executes 4,668-share tax sell-to-cover trade - Stock Titan
Voyager Therapeutics (VYGR) CSO auto-sells shares for tax bill - Stock Titan
Earnings Miss: How does Voyager Therapeutics Inc compare to its peersGlobal Markets & Accurate Buy Signal Notifications - baoquankhu1.vn
ARMISTICE CAPITAL, LLC Reduces Stake in Voyager Therapeutics Inc. - GuruFocus
4,174-Share Rule 144 Notice for Voyager Therapeutics (NASDAQ: VYGR) - Stock Titan
VYGR (NASDAQ: VYGR) Rule 144 notice: 6,458 shares tied to vesting - Stock Titan
14,197 shares vest; director sold 12,192 and 11,732 (VYGR) - Stock Titan
VYGR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Voyager Therapeutics (NASDAQ:VYGR) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
[Form 4] Voyager Therapeutics, Inc. Insider Trading Activity - Stock Titan
Is Voyager Therapeutics Inc. stock a smart retirement pickEarnings Overview Report & Daily Market Momentum Tracking - mfd.ru
Tax-driven sale: Voyager (NASDAQ: VYGR) CSO sells 3,301 shares - Stock Titan
Voyager Therapeutics (VYGR) Form 144: 3,301-share proposed sale; insider sold 3,525 - Stock Titan
EcoR1 discloses 6.8% Voyager Therapeutics (VYGR) ownership stake - Stock Titan
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Published on: 2026-02-14 07:15:36 - mfd.ru
Voyager Therapeutics Announces Chief Medical Officer Resignation - The Globe and Mail
What analyst consensus says on Voyager Therapeutics Inc. stockDividend Hike & Target Return Focused Picks - mfd.ru
Is Voyager Therapeutics Inc. subject to activist investor interestWeekly Investment Summary & Daily Chart Pattern Signals - mfd.ru
Todd Alfred Carter Sells 3,525 Shares of Voyager Therapeutics (NASDAQ:VYGR) Stock - MarketBeat
Finanzdaten der Voyager Therapeutics Inc-Aktie (VYGR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Voyager Therapeutics Inc-Aktie (VYGR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Sandrock Alfred | President and CEO |
Feb 24 '26 |
Sale |
3.79 |
14,197 |
53,807 |
484,060 |
| Jorgensen Nathan D. | Chief Financial Officer |
Feb 24 '26 |
Sale |
3.77 |
4,668 |
17,598 |
151,416 |
| Carter Todd Alfred | Chief Scientific Officer |
Feb 24 '26 |
Sale |
3.76 |
4,174 |
15,694 |
145,718 |
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):